News Conference News TCT 2025 DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure: ANDES Yael L. Maxwell November 04, 2025
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for July 2025 Caitlin E. Cox July 31, 2025
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for August 2024 Caitlin E. Cox September 03, 2024
News Daily News Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies Michael O'Riordan December 19, 2023
News Daily News Turning Back Subclinical Atherosclerosis Possible in Some Middle-Age People Todd Neale November 22, 2023
News Conference News AHA 2023 New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference? Shelley Wood November 13, 2023
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for February 2023 Shelley Wood March 01, 2023
News Conference News TCT 2022 New Faces, New Formats, New Tech: What to Expect From TCT 2022 Shelley Wood September 07, 2022
News Features ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging Michael O'Riordan March 23, 2018
News Features PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data Michael O'Riordan January 25, 2016
News Daily News Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV Michael O'Riordan December 15, 2015
News Daily News Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee Michael O'Riordan December 15, 2015